We describe a case of diabetes mellitus induced by megestrol acetate in a patient with the acquired immunodeficiency syndrome. Metabolic studies including an arginine infusion test excluded an insulinopenic state and suggested insulin resistance as the underlying mechanism for hyperglycaemia. Withdrawal of megestrol acetate resulted in rapid correction of all metabolic abnormalities and eliminated the need for exogenous insulin therapy.
Megestrol acetate, a synthetic orally active progestational agent has recently been used for the treatment of weight loss and cachexia associated with cancer and the acquired immunodeficiency syndrome (AIDS). It is thought that megestrol acetate promotes weight gain by stimulating appetite; however, the exact mechanism remains unknown. In general, the drug is well-tolerated with few potential adverse effects including peripheral oedema, impotence, menstrual irregularities, deep vein thrombosis and hyperpnea. Recently, we encountered a case of diabetes mellitus induced by megestrol acetate in a patient with AIDS.
Case report
A 36-year-old homosexual man with AIDS was admitted to hospital with a diagnosis of hyperosmolar nonketotic syndrome. One year prior to admission, the patient had suffered from Pneumocystis carinii pneumonia, successfully treated with intravenous pentamidine. Since then he had been maintained on dapsone for secondary prophylaxis without recurrence of the P carinii pneumonia. Antiretroviral therapy consisted of dideoxyinosine which was discontinued six months prior to admission because of persistent but asymptomatic elevation of pancreatic enzymes.
Physical examination revealed dehydration, mild confusion and slurring of speech. No organomegaly or signs of localised infection were noted. His height, weight and body mass index were 172 cm, 66 kg and 22.3 kg/mi, respectively.
Laboratory data included the following: blood glucose 51 mmol/l, sodium 129 mmol/l, potassium 5.4 mmol/l, bicarbonate 17 mmol/l, triglyceride 11.5 mmol/l, cholesterol 5.7 mmol/l, amylase 111 U/I (normal 7 -59 U/1), and lipase 140 U/i (normal 0-88 U/1). Arterial blood gas: pH 7.45, pCO2 20 mmHg, PO2 127 mmHg on room air. Serum osmolality was 322 mOsm/kg. Serum and urinary ketone were negative. Chest X-ray, electrocardiogram and computed tomography (CT) scan of the abdomen were normal.
Intravenous fluids and insulin were administered with resultant rapid improvement in condition. Over the next several days, the patient required up to 75 units of insulin in 24 hours for glycaemic control.
Careful review of his records revealed that the patient was started on megestrol acetate, 240 mg/day, three months prior to admission for progressive anorexia and weight loss. One week after starting megestrol acetate, hyperglycaemia was noted for the first time on random blood glucose testing. An oral glucose tolerance test six weeks later was abnormal (table  1) . Megestrol acetate induced diabetes mellitus was therefore strongly suspected and further metabolic studies were pursued. A fasting Cpeptide level was 1.09 mmol/l (normal 0.1 -1.22 mmol/l). Anti-insulin antibodies were negative. Pancreatic islet cell function was studied after intravenous infusion of arginine (0.5 g/kg over 30 min). C-Peptide, insulin and glucagon responses were normal (table 2) . These results demonstrated that islet cell function was intact. Megestrol acetate was subsequently discontinued, and insulin requirements rapidly declined, stopping altogether after one week. The patient remained euglycaemic and a repeat oral glucose tolerance test after two weeks was within normal limits (table 1) . A repeat serum triglyceride at this time was 2.86 mmol/l, also consistent with the correction of insulin resistance. A 68-year-old woman was admitted to hospital with a one-week history of profound somnolence. She had been non-specifically unwell in the preceding month and had fallen twice without any history of head injury. There was no history of anorexia, nausea, vomiting or visual disturbance. Her past medical history consisted of ischaemic heart disease, congestive cardiac failure, atrial fibrillation, cerebrovascular disease and chronic airflow limitation. Medication comprised frusemide 120 mg, spironolactone 100 mg, prednisolone 5 mg, ranitidine 150 mg, digoxin 250 yug, all daily, with isosorbide mononitrate 20 mg and nifedipine SR 10 mg both twice daily.
Clinical examination revealed no focal neurological signs but confirmed extreme drowsiness. Investigations revealed no abnormality of full blood count, urea and electrolytes, liver function tests, blood glucose, thyroid function tests or B12 and folate. Blood cultures and VDRL were negative. Chest X-ray was normal and electrocardiogram showed sinus rhythm with lateral ST depression. Computed tomography (CT) scan of brain revealed no abnormality and lumbar puncture resulted in clear, colourless cerebrospinal fluid with no growth, normal glucose and mildly raised protein at 0.63 g/l (normal <0.4 g/l). Electroencephalogram (EEG) showed focal right anterior quadrant delta slowing consistent with Herpes encephalitis. However, following a telephone conversation with her general practitioner it transpired that her digoxin dose had been doubled to 250 ug daily approximately one month prior to admission. Her digoxin level when checked was > 5 jug/l. Digoxin was withheld and the patient gradually woke up. One week later she was back to normal (digoxin level 0.3 ,ug/l). 
